Timothy Gilligan

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi request reprint Absence of a correlation of androgen receptor gene CAG repeat length and prostate cancer risk in an African-American population
    Timothy Gilligan
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Prostate Cancer 3:98-103. 2004
  2. ncbi request reprint When do we stop talking about curative care?
    Timothy Gilligan
    Dana Farber Cancer Institute, 44 Binney Street, Dana 1230, Boston, MA 02115, USA
    J Palliat Med 6:657-60. 2003
  3. ncbi request reprint Racial differences in screening for prostate cancer in the elderly
    Timothy Gilligan
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Arch Intern Med 164:1858-64. 2004
  4. ncbi request reprint Social disparities and prostate cancer: mapping the gaps in our knowledge
    Timothy Gilligan
    Department of Medicine, Department of Medical Oncology, Harvard Medical School, Dana Farber Cancer Institute, 44 Binnery St, D 1230 Boston, MA 02115, USA
    Cancer Causes Control 16:45-53. 2005
  5. ncbi request reprint Chemotherapy for prostate cancer
    Timothy Gilligan
    Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Urology 60:94-100; discussion 100. 2002
  6. ncbi request reprint Changing management of clinical low-stage testicular cancer
    Timothy Gilligan
    Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    ScientificWorldJournal 5:852-67. 2005
  7. ncbi request reprint Management of clinical stage I nonseminomatous germ cell testicular cancer
    Toni K Choueiri
    Department of Solid Tumor Oncology, Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, OH 44195 0001, USA
    Urol Clin North Am 34:137-48; abstract viii. 2007

Detail Information

Publications7

  1. ncbi request reprint Absence of a correlation of androgen receptor gene CAG repeat length and prostate cancer risk in an African-American population
    Timothy Gilligan
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Prostate Cancer 3:98-103. 2004
    ..This study confirms earlier reports that black men have shorter CAG repeat lengths than reported white and Asian populations. We did not find an increased risk of prostate cancer among black men with fewer CAG repeats...
  2. ncbi request reprint When do we stop talking about curative care?
    Timothy Gilligan
    Dana Farber Cancer Institute, 44 Binney Street, Dana 1230, Boston, MA 02115, USA
    J Palliat Med 6:657-60. 2003
  3. ncbi request reprint Racial differences in screening for prostate cancer in the elderly
    Timothy Gilligan
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Arch Intern Med 164:1858-64. 2004
    ..Low screening rates among black men may contribute to these disparities, but there are few data on racial differences in prostate cancer screening...
  4. ncbi request reprint Social disparities and prostate cancer: mapping the gaps in our knowledge
    Timothy Gilligan
    Department of Medicine, Department of Medical Oncology, Harvard Medical School, Dana Farber Cancer Institute, 44 Binnery St, D 1230 Boston, MA 02115, USA
    Cancer Causes Control 16:45-53. 2005
    ..Understanding the causes of the high prostate cancer mortality seen among black men remains the major challenge in the area of social disparities and prostate cancer...
  5. ncbi request reprint Chemotherapy for prostate cancer
    Timothy Gilligan
    Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Urology 60:94-100; discussion 100. 2002
    ..Finally, the utility of chemotherapy is beginning to be explored in the context of earlier disease in the neoadjuvant, adjuvant, or serologically relapsing group of patients. Data from these studies are just beginning to be gathered...
  6. ncbi request reprint Changing management of clinical low-stage testicular cancer
    Timothy Gilligan
    Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    ScientificWorldJournal 5:852-67. 2005
    ..Clinical studies have made it possible to identify subgroups of patients at high and low risk for relapse and this has made it possible to tailor treatment decisions to the individual patient's postorchiectomy relapse risk...
  7. ncbi request reprint Management of clinical stage I nonseminomatous germ cell testicular cancer
    Toni K Choueiri
    Department of Solid Tumor Oncology, Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, OH 44195 0001, USA
    Urol Clin North Am 34:137-48; abstract viii. 2007
    ..For patients at high risk for relapse and who are not candidates for surveillance, we believe the evidence supports RPLND over primary chemotherapy...